Solvay, Bristol obesity drug advances in trials
(Reute


<p><a href="http://us.rd.yahoo.com/dailynews/rss/health/*http://news.yahoo.com/s/nm/20061208/hl_nm/solvay_obesity_dc"><img src="http://d.yimg.com/us.yimg.com/p/nm/20061208/2006_12_08t052138_450x321_us_solvay_obesity.jpg?x=130&y=92&sig=w.gywgDaFFM_HQU9Ifr7Ew--" align="left" height="92" width="130" alt="A laboratory researcher in a file photo. A new anti-obesity drug that works in the same way as Sanofi-Aventis's Acomplia has advanced in clinical trials, triggering a $25 million payment to Belgian drugs, chemicals and plastics maker Solvay. (Sebastian Derungs/Reuters)" border="0" /></a>Reuters - A new anti-obesity drug that works in
the same way as Sanofi-Aventis's Acomplia has advanced in
clinical trials, triggering a $25 million payment to Belgian
drugs, chemicals and plastics maker Solvay.</p><br clear="all"/>